CTOs on the Move

Accugenix

www.accugenix.com

 
Accugenix offers a fixed pricing structure based upon turnaround time requirements. Whether your isolates are routine or require immediate attention, we have the operational flexibility and capacity to meet your needs. We also offer volume pricing
  • Number of Employees: 5K-10K
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Qualyst

Qualyst is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GlaxoSmithKline

We are a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. As one of the few healthcare companies researching both medicines and vaccines for the World Health Organization`s three priority diseases – HIV/AIDS, tuberculosis and malaria, we are very proud to have developed some of the leading global medicines in these fields. Our product portfolio also includes a range of consumer brands, many of which are household names around the world, including Sensodyne, Aquafresh, Horlicks, Panadol and Tums.

Metro Vein Centers

Metro Vein Centers is a network of trusted vein specialists and vascular surgeons, specializing in varicose veins, spider veins and other venous conditions. Book your appointment online!

Sigma-Tau PharmaSource

Sigma-Tau PharmaSource is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Deciphera

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.